Background: There has been considerable debate on the management of the axilla in breast cancer patients with lymph node metastasis found on sentinel lymph node biopsy (SLNB) following publication of the ACOSOG Z0011 study. This study conclude that axillary lymph node dissection (ALND) does not add any benefit to overall and disease free survival in some patients with positive SLNB. However it is not know if the patient characteristics of this study are transferable to other settings. A previous UK study has suggested that only a minority of patients from an academic specialist centre fit the ASOCOG Z0011 criteria and that the patient populations may not be comparable. The aim of our study was to assess the applicability of the Z0011 study to our patient population of a large District General Hospital in the UK and to what extent it should influence our practice. Methods: The Z0011 eligibility criteria for inclusion in analysis were applied to all patients undergoing SLNB for invasive cancer at West Hertfordshire Breast Unit from 2007–2011. These were: no neo-adjuvant chemotherapy, clinical T1 and T2 tumours, breast conserving surgery followed by whole breast radiotherapy and 1–3 positive nodes on SLNB. Patent characteristics and results were compared using fisher's exact test. Results: In our unit a total of 434 patients underwent SNLB of whom 64(14.7%) met the inclusion criteria of Z0011. Our patient population was comparable to that of Z0011 with regards to lymphovascular invasion, proportion of patients with micro-metastases and those with additional lymph nodes found on completion ALND. Our patients had significantly more T2 tumours. The only other statistically significant difference was in the proportion of estrogen receptor(ER) and progestrogen receptor (PR) positivity. Conclusion: Only a small proportion (14%) of patients undergoing SNLB in our patient population fit the criteria for Z0011. This was a higher proportion than in the previous UK study of this type. Similar to this study we found the proportion of patients with T2 tumours were greater in our patient population compared to Z0011. This is most likely a reflection of this unit not being a screening centre and brings in to question the international generalisability of Z0011. However the only other significant difference in our patients was a lower risk profile in terms of hormone rector positivity with more ER/PR positive and fewer ER/PR negative patients. The implications of Z0011, will in our practice, not make a significant difference to the rate of ANLD. We are however considering changing our patient management based on the result of Z0011 and this current study of our population, to offer no further axillary surgery to patients over 50 with T1 and ER/PR positive tumours who otherwise fit the Z0011 protocol. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-07-01.
Background≤br≥Between 2002 and 2011, in the UK, the number of people aged 90 increased by 26%. By 2034 the number of people aged 85 and over, is projected to be 2.5 times larger than in 2009. Life expectancy of 80 year old woman is now 9.4 years. These population statistics bring challenges to the provision of healthcare in general and Breast Cancer Services will see a significant increase in the number of very elderly patients. Prior to 2009 it was common place to treat patients aged over 80 with endocrine therapy alone, avoiding surgery, however as the general life expectancy for this age group has improved this is no longer recommended management. NICE guidelines issued in February 2009 recommend surgery for breast cancer where possible over endocrine treatment We aim to review the proportion of patients presenting with breast cancer aged over 80, assess their management and survival during a 12 year period and audit patients presenting after 2009 against NICE guideline to explore reasons for noncompliance. Methods We have conducted a retrospective audit of all patients presenting with breast cancer to a single high-volume center from 2000-2012. Patients were identified from a comprehensive departmental database recording patient demographics as well as treatment modality. For patients treated after 2009, case records were accessed to assess the reasons for omitting surgery. One-tailed Fisher's Exact Test used throughout to calculate p-values. Results≤br≥5446 patients were treated at our unit from 2000-2012 with the over 80's comprising 6.0-8.7% p.a. This age group increased over time by 29% from 6.5% in 2000-2003 to 8.4% (p = 0.0001) in 2009-2012. The population aged 90 or over increased by around 50% from 1.7% to 2.6% (p = 0.06) in the same period. The table below shows changes in the proportion of patients offered surgery before and after the 2009 guidelines. Patients Undergoing Breast Cancer SurgeryPatients aged 80-89Patients aged 90 and over2000- 20082009-2012p-value2000-20082009-2012p-value267/396 (67%)172/230 (75%)0.0318/64 (28%)21/47 (44%)0.05 Following introduction of regional anaesthesia without General Anasthesia in 2011, the proportion of patients aged over 90 having surgery, increased further to 16/25 (64% p-0.0031). In the 10 year period from 2001-2010 the mastectomy rate was 60% in the over 80's and 45% in the over 90 year old, however this difference was not statistically significant (p = 0.29). We have accurate survival data for 396 patients who died during follow up. No patients died within 12 months of surgery. The median survival was 40 months following surgery and 27 months for patients treated with primary endocrine therapy. 16/218 patients aged 80-89 and 2/111 patients aged over 90 at diagnosis required resectional surgery after relapse on primary endocrine therapy. Of patients not having surgery after 2009, 48 were deemed unfit and 36 declined surgery. Conclusions≤br≥The elderly is a growing part of our population of breast cancer patients. We have increased the proportion of elderly patient having surgery in line with NICE guidance, partly due regional anaesthesia for breast surgery and modification of care pathways. The relapse rate following primary endocrine therapy was very low in the most elderly patients. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-18-17.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.